TEANECK, N.J., Jan. 25, 2016 -- Phibro Animal Health Corporation (“Phibro”) (NASDAQ:PAHC) today announced it has completed its purchase of the assets of MVP Laboratories, Inc. (“MVP”), a developer, manufacturer and marketer of livestock vaccines, vaccine adjuvants and other products based in Omaha, Nebraska. Phibro previously announced an agreement to purchase the assets of MVP Laboratories, Inc. on January 12, 2016.
About Phibro Animal Health Corporation
Phibro Animal Health Corporation is a diversified global developer, manufacturer and marketer of a broad range of animal health and mineral nutrition products for use in the production of poultry, swine, cattle, dairy and aquaculture. The company reported net sales of $749 million for the fiscal year ended June 30, 2015. For further information, please visit www.pahc.com.
Forward-Looking Statements
This communication contains forward-looking statements, which reflect Phibro’s current views with respect to business plans or prospects, the transactions described herein, and other future events. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “aim,” “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “outlook,” “potential,” “project,” “projection,” “plan,” “intend,” “seek,” “believe,” “may,” “could,” “would,” “will,” “should,” “can,” “can have,” “likely,” the negatives thereof and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management’s underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Phibro expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, including in the sections thereof captioned “Forward-Looking Statements” and “Risk Factors.” These filings and subsequent filings are available online at www.sec.gov, www.pahc.com, or on request from Phibro.
Contact Phibro Animal Health Corporation Richard Johnson Chief Financial Officer +1-201-329-7300 [email protected]


TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
OpenAI Explores Massive Funding Round at $750 Billion Valuation
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 



